CYTOMX THERAPEUTICS INC (CTMX) Stock Price & Overview
NASDAQ:CTMX • US23284F1057
Current stock price
The current stock price of CTMX is 4.25 USD. Today CTMX is down by -1.16%. In the past month the price decreased by -12.91%. In the past year, price increased by 698.12%.
CTMX Key Statistics
- Market Cap
- 720.12M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.04
- Dividend Yield
- N/A
CTMX Stock Performance
CTMX Stock Chart
CTMX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CTMX. When comparing the yearly performance of all stocks, CTMX is one of the better performing stocks in the market, outperforming 99.35% of all stocks.
CTMX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CTMX. The financial health of CTMX is average, but there are quite some concerns on its profitability.
CTMX Earnings
On March 16, 2026 CTMX reported an EPS of -0.22 and a revenue of 663.00K. The company missed EPS expectations (-130.26% surprise) and missed revenue expectations (-91.77% surprise).
CTMX Forecast & Estimates
15 analysts have analysed CTMX and the average price target is 13.9 USD. This implies a price increase of 227% is expected in the next year compared to the current price of 4.25.
For the next year, analysts expect an EPS growth of -854.5% and a revenue growth -71.08% for CTMX
CTMX Groups
Sector & Classification
CTMX Financial Highlights
Over the last trailing twelve months CTMX reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS decreased by -110.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.44% | ||
| ROE | -20.57% | ||
| Debt/Equity | 0 |
CTMX Ownership
CTMX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.26 | 364.897B | ||
| AMGN | AMGEN INC | 15.33 | 183.284B | ||
| GILD | GILEAD SCIENCES INC | 16.01 | 172.309B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.9 | 109.705B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 80.376B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.86 | 42.375B | ||
| INSM | INSMED INC | N/A | 35.141B | ||
| NTRA | NATERA INC | N/A | 29.66B | ||
| BIIB | BIOGEN INC | 11.19 | 25.773B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.48 | 24.795B | ||
| MRNA | MODERNA INC | N/A | 19.79B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.082B | ||
| INCY | INCYTE CORP | 12.52 | 18.645B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CTMX
Company Profile
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company is headquartered in South San Francisco, California and currently employs 69 full-time employees. The company went IPO on 2015-10-08. The firm is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The firm is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
Company Info
IPO: 2015-10-08
CYTOMX THERAPEUTICS INC
151 Oyster Point Blvd., Suite 400
South San Francisco CALIFORNIA 94080 US
CEO: Sean A. McCarthy
Employees: 120
Phone: 16505153185
CYTOMX THERAPEUTICS INC / CTMX FAQ
What does CTMX do?
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company is headquartered in South San Francisco, California and currently employs 69 full-time employees. The company went IPO on 2015-10-08. The firm is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The firm is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
What is the current price of CTMX stock?
The current stock price of CTMX is 4.25 USD. The price decreased by -1.16% in the last trading session.
What is the dividend status of CYTOMX THERAPEUTICS INC?
CTMX does not pay a dividend.
How is the ChartMill rating for CYTOMX THERAPEUTICS INC?
CTMX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of CTMX stock?
CYTOMX THERAPEUTICS INC (CTMX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for CYTOMX THERAPEUTICS INC?
CYTOMX THERAPEUTICS INC (CTMX) currently has 120 employees.
What is CYTOMX THERAPEUTICS INC worth?
CYTOMX THERAPEUTICS INC (CTMX) has a market capitalization of 720.12M USD. This makes CTMX a Small Cap stock.